Geron (GERN) Total Liabilities (2010 - 2026)
Geron (GERN) posted Total Liabilities of $305.0 million for Q1 2026, down 11.51% sequentially from $344.7 million in Q4 2025, and down 45.77% YoY from $562.4 million in Q1 2025.
Geron (GERN) Total Liabilities (2010 - 2026) Analysis & Trends
Geron has reported Total Liabilities for 17 years, with the latest figure at $305.0 million in Q1 2026.
- Quarterly Total Liabilities fell 45.77% year-over-year to $305.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $305.0 million (down 45.77% YoY) and the FY2025 annual result came in at $344.7 million, up 9.96% from the prior year.
- Total Liabilities slipped to $305.0 million in Q1 2026 per GERN's latest filing, from $344.7 million in the prior quarter.
- Over five years, Total Liabilities peaked at $567.4 million in Q3 2025 and troughed at $110.6 million in Q4 2022.
- A 5-year average of $364.9 million and a median of $413.0 million in 2023 frame the typical range for Total Liabilities.
- The sharpest annual moves came in 2024 and 2026: Total Liabilities jumped 114.51% in 2024, then plunged 45.77% in 2026.
- Over 5 years, Total Liabilities stood at $110.6 million in 2022, then surged by 32.15% to $146.1 million in 2023, then surged by 114.51% to $313.5 million in 2024, then gained by 9.96% to $344.7 million in 2025, then slipped by 11.51% to $305.0 million in 2026.
- According to Business Quant data, Total Liabilities over the past three periods registered $305.0 million, $344.7 million, and $567.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.09 Bn | 131.23 Bn | 2.84 Bn | 7.18 Bn |
| 2 | Regeneron Pharmaceuticals | 85.66 Bn | 77.66 Bn | 3.93 Bn | 10.02 Bn |
| 3 | Argenx Se | 64.86 Bn | 59.67 Bn | 1.37 Bn | 1.62 Bn |
| 4 | Moderna | 58.07 Bn | 52.93 Bn | 52.00 Mn | 4.20 Bn |
| 5 | BeOne Medicines | 41.87 Bn | 36.77 Bn | 1.53 Bn | 4.00 Bn |
| 6 | Alnylam Pharmaceuticals | 31.45 Bn | 28.15 Bn | 992.69 Mn | 4.20 Bn |
| 7 | BioNTech SE | 27.90 Bn | 9.51 Bn | 668.28 Mn | 3.22 Bn |
| 8 | Insmed | 27.40 Bn | 26.24 Bn | 358.27 Mn | 1.35 Bn |
| 9 | Royalty Pharma | 27.28 Bn | 26.45 Bn | - | 10.03 Bn |
| 10 | Geron | 1.02 Mn | -299.83 Mn | - | 300.40 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 300.40 Mn |
| Mar 31, 2026 | 305.01 Mn |
| Dec 31, 2025 | 344.67 Mn |
| Sep 30, 2025 | 567.38 Mn |
| Jun 30, 2025 | 555.20 Mn |
| Mar 31, 2025 | 562.45 Mn |
| Dec 31, 2024 | 313.46 Mn |
| Sep 30, 2024 | 444.95 Mn |
| Jun 30, 2024 | 449.40 Mn |
| Mar 31, 2024 | 482.07 Mn |
| Dec 31, 2023 | 146.13 Mn |
| Sep 30, 2023 | 413.02 Mn |
| Jun 30, 2023 | 415.30 Mn |
| Mar 31, 2023 | 424.88 Mn |
| Dec 31, 2022 | 110.58 Mn |
| Sep 30, 2022 | 232.61 Mn |
| Jun 30, 2022 | 238.16 Mn |
| Mar 31, 2022 | 198.42 Mn |
| Dec 31, 2021 | 99.62 Mn |
| Sep 30, 2021 | 229.10 Mn |